-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 26, OncoC4 announced that the U.
PD-1/L1 inhibitor-resistant non-small cell lung cancer is one of the clinical challenges of immunotherapy, and there is a huge unmet medical need
As a new generation of anti-CTLA-4 monoclonal antibody, ONC-392 can more effectively and selectively remove regulatory T cells in the tumor microenvironment, which is an important part of tumor immune escape The main "culprit"
Currently, ONC-392 is undergoing a Phase 1 clinical study overseas (PRESERVE-001 study) to evaluate its safety, pharmacokinetics, and efficacy as monotherapy and in combination with anti-PD-1 standard therapy in advanced solid tumors and NSCLC.
In China, OncorImmune is conducting a Phase 1 clinical study of ONC-392, which aims to evaluate the safety, tolerability and pharmacokinetics of the drug as a monotherapy for advanced solid tumors in the Chinese population